A peripherally acting μ-opioid receptor antagonist for treating opioid-associated tinnitus: A case report

Satoru Ogawa1, Fumimasa Amaya1

  • 1Department of Pain Management and Palliative Care Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Palliative Medicine
|July 29, 2024
PubMed
Abstract

Insights

Peripherally acting μ-opioid receptor antagonists effectively treated opioid-associated tinnitus in a cancer patient. This approach managed tinnitus without impacting pain control, offering a new therapeutic option.

Area of Science:

  • Oncology
  • Pharmacology
  • Pain Management

Background:

  • Opioid use can cause tinnitus, a condition with limited research regarding management in cancer patients.
  • Opioid-induced tinnitus poses a challenge, as discontinuing opioids may compromise pain management in cancer care.

Observation:

  • A pancreatic cancer patient developed tinnitus during opioid therapy (oxycodone, hydromorphone, tapentadol).
  • Tinnitus resolved upon opioid cessation but recurred with re-administration, indicating a direct drug effect.

Findings:

  • Naldemedine, a peripherally acting μ-opioid receptor antagonist, was administered at 200 μg/day for tinnitus relief.
  • Tinnitus resolved immediately upon naldemedine initiation, and pain control was maintained.

Implications:

  • Peripherally acting μ-opioid receptor antagonists may offer a viable strategy for managing opioid-associated tinnitus in cancer patients.
  • This treatment allows for continued opioid analgesia while addressing tinnitus, improving patient quality of life.
  • Further research is needed to explore the broader effects of these antagonists on opioid-related complications beyond constipation.

Related Concept Videos

Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
557
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
650
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
260
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
210